All the news Showing 10 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people Liz Highleyman / 23 November 2016 A new three-drug co-formulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2 or 3, with sustained response rates ... 8-week triple DAA combo cures most people with genotype 1-6 hepatitis C Liz Highleyman / 21 November 2016 A three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated people with all hepatitis C virus (HCV) genotypes, while ... AbbVie pangenotypic combination cures 98% or above across genotypes Keith Alcorn / 16 November 2016 AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in three large clinical trials covering five out of six genotypes of the virus, and is ... AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3 Keith Alcorn / 16 November 2016 AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 patients – those with cirrhosis and/or previous treatment experience – in a phase II trial, and looks suitable ... Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients Liz Highleyman / 14 November 2016 A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching ... New triple DAA combo cures 96-99% of people with all genotypes of hepatitis C Liz Highleyman / 08 November 2016 A new three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated people with all hepatitis C virus (HCV) genotypes, while ... AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... 100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks Liz Highleyman / 05 October 2016 A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis ... Hepatitis C vaccine development shows progress but scientific barriers remain Liz Highleyman / 12 September 2016 An effective vaccine may be necessary to eliminate hepatitis C virus (HCV) but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations ... US regulators approve Gilead's Epclusa combo pill for all hepatitis C genotypes Liz Highleyman / 04 July 2016 On June 28 the US Food and Drug Administration approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes ... ← Prev1...23456...23Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive